Systemic inflammatory markers in elderly patients undergoing transcatheter aortic valve replacement

[1]

Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017: 1321-1331.

[2] Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374: 1609−1620. doi: 10.1056/NEJMoa1514616 [3] Yamamoto M, Meguro K, Mouillet G, et al. Comparison of effectiveness and safety of transcatheter aortic valve implantation in patients aged ≥ 90 years versus Am J Cardiol 2012; 110: 1156−1163. doi: 10.1016/j.amjcard.2012.05.058 [4] Braghiroli J, Kapoor K, Thielhelm TP, et al. Transcatheter aortic valve replacement in low risk patients: a review of PARTNER 3 and Evolut low risk trials. Cardiovasc Diagn Ther 2020; 10: 59. doi: 10.21037/cdt.2019.09.12 [5] Schwietz T, Behjati S, Gafoor S, et al. Occurrence and prognostic impact of systemic inflammatory response syndrome in transfemoral and transapical aortic valve implantation with balloon-and self-expandable valves. EuroIntervention 2015; 10: 1468−1473. doi: 10.4244/EIJY14M06_05 [6] Neuser J, Galuppo P, Fraccarollo D, et al. Intermediate CD14++ CD16+ monocytes decline after transcatheter aortic valve replacement and correlate with functional capacity and left ventricular systolic function. PloS One 2017; 12: e0183670. doi: 10.1371/journal.pone.0183670 [7] Sinning JM, Adenauer V, Scheer AC, et al. Systemic Inflammatory Response Syndrome Predicts Increased Mortality in Patients After Transcatheter Aortic Valve Implantation. Eur Heart J 2012; 33: 1459−1468. doi: 10.1093/eurheartj/ehs002 [8] Abu Khadija H, Gandelman G, Ayyad O, et al. Differential systemic inflammatory responses after TAVI: The role of self versus balloon expandable devices. PloS One 2021; 16: e0258963. doi: 10.1371/journal.pone.0258963 [9] Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008; 102: 653−657. doi: 10.1016/j.amjcard.2008.05.006 [10]

Alves P, Ferreira B. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly 2008; 138: 534−539.

[11] Çakıcı M, Çetin M, Doğan A, et al. Neutrophil to lymphocyte ratio predicts poor functional capacity in patients with heart failure. Turk Kardiyol Dern Ars 2014; 42: 612−620. doi: 10.5543/tkda.2014.16363 [12] Balta S, Demirkol S, Celik T, et al. Association between coronary artery ectasia and neutrophil–lymphocyte ratio. Angiology 2013; 64: 627−632. doi: 10.1177/0003319713480424 [13] Abu Khadija H, Gandelman G, Ayyad O, et al. Comparative analysis of the kinetic behavior of systemic inflammatory markers in patients with depressed versus preserved left ventricular function undergoing transcatheter aortic valve implantation. J Clin Med 2021; 10: 4148. doi: 10.3390/jcm10184148 [14] Abu Khadija H, Ayyad O, Haberman D, et al. Contemporary transcatheter aortic valve implantation related thrombocytopenia. Catheter Cardiovasc Interv 2021; 98: E139−E144. doi: 10.1002/ccd.29679 [15] Abu Khadija H, Gandelman G, Ayyad O, et al. Trends in transfemoral aortic valve implantation related thrombocytopenia. J Clin Med 2022; 11: 726. doi: 10.3390/jcm11030726 [16] Attinger-Toller A, Ferrari E, Tueller D, et al. Age-related outcomes after transcatheter aortic valve replacement: insights from the SwissTAVI registry. JACC Cardiovasc Interv 2021; 14: 952−960. doi: 10.1016/j.jcin.2021.01.042 [17]

van der Kley F, van Rosendael PJ, Katsanos S, et al. Impact of age on transcatheter aortic valve implantation outcomes: a comparison of patients aged ≤ 80 years versus patients > 80 years. J Geriatr Cardiol 2016; 13: 31.

[18]

Pascual I, Hernández-Vaquero D, Alperi A, et al. Survival in elderly patients with transcatheter aortic valve implants compared with the general population. Revista Españ ola de Cardiología (English Edition) 2020; 73: 822−827.

[19] Barbanti M, Webb JG, Gilard M, et al. Transcatheter aortic valve implantation in 2017: state of the art. EuroIntervention 2017; 13: AA11−AA21. doi: 10.4244/EIJ-D-17-00567 [20] Hoffmann J, Mas‐Peiro S, Berkowitsch A, et al. Inflammatory signatures are associated with increased mortality after transfemoral transcatheter aortic valve implantation. ESC Heart Fail 2020; 7: 2597−2610. doi: 10.1002/ehf2.12837 [21]

Hoffmann J, Mas-Peiro S, Boeckling F, et al. Inflammatory phenotypes of circulating leukocyte subsets are associated with increased mortality after transfemoral transcatheter aortic valve implantation. Circulation 2019; 140: A15461−A15461.

[22] Urena M, Webb JG, Tamburino C, et al. Permanent pacemaker implantation after transcatheter aortic valve implantation: impact on late clinical outcomes and left ventricular function. Circulation 2014; 129: 1233−1243. doi: 10.1161/CIRCULATIONAHA.113.005479 [23] Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995; 91: 1872−1885. doi: 10.1161/01.CIR.91.6.1872 [24] Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440−1445. doi: 10.1161/01.CIR.0000090690.67322.51 [25] Chavan V, Patil N. Study of leukocytic hydrolytic enzymes in patients with acute stage of coronary heart disease. Indian J Med Sci 2007; 61: 73−82. doi: 10.4103/0019-5359.30347 [26] Ommen SR, Gibbons RJ, Hodge DO, Thomson SP. Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. Am J Cardiol 1997; 79: 812−814. doi: 10.1016/S0002-9149(96)00878-8

留言 (0)

沒有登入
gif